FDA Advances Menopause Care Through Updated Hormone Therapy Labels and Efforts to Expand Supply

By
Assistant Secretary for Public Affairs (ASPA)
October 30, 2026

United States Department Of Health And Human Services

Objective:

The article examines the objective, findings, and clinical context described in FDA Advances Menopause Care Through Updated Hormone Therapy Labels and Efforts to Expand Supply.

Approach:

Label revisions: FDA approved revised labeling for three additional MHT products, all estradiol transdermal patches, following reassessment of scientific literature and benefit–risk information.
Supply monitoring: FDA reported ongoing discussions with manufacturers, monitoring of multiple MHT formulations, and use of regulatory flexibilities related to compounding.

Key Findings:

The three patches’ boxed warnings no longer include statements about cardiovascular disease, breast cancer, or probable dementia.
The action follows February 2026 labeling changes for six MHT products. Since November 2025, 29 drug companies have submitted proposed labeling changes.
FDA reported no imminent risk of a nationwide shortage based on current information, while acknowledging localized difficulty obtaining some products.
Manufacturers have expanded patch production through increased capacity, additional shifts, and prioritization; FDA reported that total market output doubled over the past 12 months.
FDA is monitoring other dosage forms, including gels and creams, and described compounding pathways subject to specified conditions.
FDA is working with sponsors to assess whether vaginal estrogen products could be made available over the counter; this would require FDA approval based on evidence of safe and effective consumer use.

Interpretation:

The announcement describes FDA actions on MHT labeling alongside efforts to monitor supply and address access concerns.

Limitations:

The source provides no product names, applicant names, or detailed evidence from the scientific reassessment.
The source does not quantify localized access problems or provide product-specific supply data.